HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer.

Abstract
Targeted therapy based on ALK tyrosine kinase inhibitors (ALK-TKIs) has made significant achievements in individuals with EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) fusion positive nonsmall-cell lung cancer (NSCLC). However, a high fraction of patients receive inferior clinical response to such treatment in the initial therapy, and the exact mechanisms underlying this process need to be further investigated. In this study, we revealed a persistently activated PI3K/AKT signaling that mediates the drug ineffectiveness. We found that genetic or pharmacological inhibition of ALK markedly abrogated phosphorylated STAT3 and ERK, but it failed to suppress AKT activity or induce apoptosis, in EML4-ALK-positive H2228 cells. Furthermore, targeted RNA interference of PI3K pathway components restored sensitivity to TAE684 treatment at least partially due to increased apoptosis. Combined TAE684 with PI3K inhibitor synergistically inhibited the proliferation of EML4-ALK-positive cells in vitro and significantly suppressed the growth of H2228 xenografts in vivo, suggesting the potential clinical application of such combinatorial therapy regimens in patients with EML4-ALK positive lung cancer.
AuthorsLin Yang, Guangchao Li, Likun Zhao, Fei Pan, Jiankun Qiang, Siqi Han
JournalTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (Tumour Biol) Vol. 35 Issue 10 Pg. 9759-67 (Oct 2014) ISSN: 1423-0380 [Electronic] Netherlands
PMID24972969 (Publication Type: Journal Article)
Chemical References
  • EML4-ALK fusion protein, human
  • NVP-TAE684
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Phosphatidylinositol 3-Kinases
  • ALK protein, human
  • Alk protein, mouse
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases
Topics
  • Anaplastic Lymphoma Kinase
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Apoptosis (drug effects)
  • Carcinoma, Non-Small-Cell Lung (genetics, metabolism)
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm (physiology)
  • Heterografts
  • Humans
  • Immunoblotting
  • Lung Neoplasms (genetics, metabolism)
  • Mice
  • Oncogene Proteins, Fusion (antagonists & inhibitors)
  • Phosphatidylinositol 3-Kinases (metabolism)
  • Protein Kinase Inhibitors (pharmacology)
  • Pyrimidines (pharmacology)
  • Receptor Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Signal Transduction (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: